The new “2024 Glaucoma Surgical Device Market Report” provides an in-depth look at a record 18 early-stage glaucoma device and laser companies. Iantrek, led by one of ophthalmology’s most prolific innovators, is preparing to launch several revolutionary glaucoma treatments, including the AlloFlo, the first biotissue stent.
Several promising new subconjunctival products are also examined. These include Avisi Technologies’ ultrathin filtration plate implant, Myra Vision’s adjustable post-op shunt, and Ciliatech’s uveoscleral filtration acrylic plate.
The report also highlights emerging laser technologies that have the potential to dramatically expand the use of lasers in glaucoma, such as the Belkin DSLT laser, ViaLase femtosecond laser, Elios ELT laser, and IOPtimate CO2 laser.
In addition, the report tracks advancements in sustained drug delivery devices, providing insights into ongoing progress in this field.
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.